Taysha Gene Therapies' stock IPO process has kicked off in what promises to expand options for investors in the healthcare sector. The biotech startup develops treatments for CNS (central nervous system) disorders. Its lead candidate, TSHA-101, is set to begin clinical trials in Canada for treating GM2 gangliosidosis, a rare genetic disorder.
When is the Taysha Gene Therapies IPO date?
Taysha Gene Therapies filed its IPO proposal with the SEC on Sept. 2. It went on to set the terms for its public listing on Sept. 17. The IPO seeks to raise $125 million from the sale of 6.6 million shares. The company gave a pricing range of $18–$20.
Taysha has yet to set a date for its IPO. However, IPO stocks often make their debut on the public market soon after pricing. The company is expected to price its IPO this week. Taysha stock will trade on the Nasdaq under the “TSHA” ticker symbol.
Should you buy Taysha Gene Therapies IPO stock?
Taysha Gene Therapies stock may be a good fit for investors seeking exposure to the CNS therapy market. The global CNS therapy market is on track to grow to $128.9 billion in 2025 from $77.2 billion in 2016.
Investors considering Taysha stock should know that the company is not currently generating revenue. It recorded a loss of $1.1 million in the fourth quarter of 2019, and had $11.2 million in cash and $20 million in liabilities at the end of June 2020. Taysha investors include Fidelity Management, PBM Capital Group, and UT Southwestern. The company intends to use its IPO proceeds to advance its pipeline.
Where to buy into the Taysha Gene Therapies stock IPO
In an IPO, shares are first sold to accredited investors—often large institutional investors such as pension funds—through underwriting brokers. Once a stock debuts on the public market, every investor can buy it.
If you're shopping for where to buy Taysha stock, consider online brokers such as Robinhood, Webull, SoFi Invest, Vanguard, M1 Finance, Tastyworks, Cash App Investing, and Interactive Brokers. Some of these online stockbrokers allow investors to purchase fractional shares from as little as $1.
Introducing Fractional Shares! Invest in thousands of stocks and ETFs on Robinhood with as little as $1, regardless of whole share prices.— Robinhood (@RobinhoodApp) December 12, 2019
We know this was a popular request and we’re excited to start launching next week! Sign up for early access. 🚀https://t.co/SmChwAWOlb pic.twitter.com/b8W4dgK3jA
How to buy into the Taysha Gene Therapies stock IPO on Robinhood
Robinhood's trading platform allows you to buy and sell stocks and other securities commission-free. The platform cuts investing costs and has expanded access to the stock market for small-budget investors.
You can buy Taysha stock on Robinhood by first setting up a trading account and funding it. Robinhood offers three account types: Robinhood Cash, Robinhood Instant, and Robinhood Gold. Investors with a Robinhood Gold account have access to trading loans and stock research reports from Morningstar. Robinhood’s pre-IPO stock purchase feature allows investors to buy newly public stocks just as they hit the market.